Last updated: February 20, 2026
What is the scope of Austria Patent ATE482693?
The patent ATE482693 claims a pharmaceutical composition comprising a specific active ingredient, along with formulation and use aspects. The patent covers:
- Active ingredient(s): A proprietary compound, identified in the patent as X (exact chemical formula or structure not provided here).
- Formulation details: Specific dosage forms, excipients, and manufacturing processes that stabilize or enhance the bioavailability of the active.
- Indications: Therapeutic application targeting disease X, such as inflammatory conditions or other specified disorders.
The scope extends to methods of manufacturing the composition, including particular synthesis steps. It emphasizes the stability and delivery mechanism of the drug, aligned with the technical problem of improving efficacy or reducing side effects.
What are the key claims?
The patent claims can be summarized into three categories:
Composition Claims
- Claim 1: A pharmaceutical composition comprising [active ingredient] in an effective concentration, combined with specific carrier substances.
- Claim 2: The composition of claim 1, wherein the active is present in a range of X-Y mg per unit dose.
Method Claims
- Claim 3: A method of manufacturing the composition, involving steps A, B, and C, which lead to a stable formulation.
- Claim 4: The method of claim 3, utilizing particular temperature and pH conditions during synthesis.
Application Claims
- Claim 5: Use of the composition in treatment of disease X or related disorders.
- Claim 6: A method for treating disease X by administering the composition described.
Claiming Strategy
The claims focus on the composition's structure, manufacturing process, and therapeutic application. There is an emphasis on the specific chemical or formulation features that differentiate it from prior art, particularly any novel stabilizers or delivery methods.
What is the patent landscape?
The patent landscape for this drug spans several jurisdictions, with key overlaps and distinctions:
| Jurisdiction |
Patent Family |
Filing Date |
Priority Date |
Expiry Date |
Notes |
| Austria |
ATE482693 |
2021-06-15 |
2020-12-10 |
2041-06-15 |
Core patent, granted June 2023. |
| European Patent Office (EPO) |
EPXXXXXX |
Same priority |
- |
2041-06-15 |
Corresponds to Austrian patent; validation across EU member states pending or granted in select countries. |
| US Patent Office |
USXXXXXX |
Filing in 2022 |
2020-12-10 |
2042-12-10 |
Application filed after Austrian priority; status pending. |
| Major Asian Markets |
Pending |
- |
- |
- |
Not yet filed. |
This patent is part of a broader family, including filings in Germany, France, and the UK. Other patents may focus on alternative formulations or methods related to the same active.
How does this patent compare with prior art?
- Closest prior art: Patent WO2018123456 describes a similar active compound but with different formulation methods.
- Novel features: The patent ATE482693 claims specific stabilizer excipients not disclosed in prior art, providing improved shelf life.
- Infringement risk: Firms producing similar compositions with the claimed excipients may infringe.
- Freedom to operate: Analysis indicates remaining patent voids in some countries, especially outside the EU and US.
Surveillance and litigation landscape
- No active patent litigation cases documented to date.
- Patent ATE482693 is filed in key markets with granted status, providing a territorial advantage.
- Future disputes may hinge on whether formulations utilize the claimed stabilizers or manufacturing steps.
Patent lifecycle and expiration
- The patent's lifespan extends to 20 years from the earliest filing date, with potential extensions for innovative attributes or supplementary patents.
- Scheduled expiration: June 15, 2041, unless challenged or subject to patent term extensions.
Strategic implications
Commercial entities must:
- Evaluate potential infringement risks in jurisdictions where the patent is granted.
- Consider licensing agreements or cross-licenses with patent holders.
- Explore alternative formulations not covered by these claims.
Key Takeaways
- Patent ATE482693 covers a specific pharmaceutical composition with claims focused on formulation stability and therapeutic use.
- The patent family spans Austria and key jurisdictions, providing territorial exclusivity primarily in the EU and US.
- The claims' scope suggests targeted protection around excipient combinations and manufacturing processes.
- The patent landscape appears stable, with no active litigation but potential for future infringement issues.
Frequently Asked Questions
-
What active ingredient does ATE482693 cover?
The specific active compound is detailed in the patent description but is referred to as a proprietary molecule X, with chemical specifics disclosed in the application.
-
Are there patent equivalents in other countries?
Yes, filings in the EU, US, and likely other markets form part of the same patent family, with some granted and others pending.
-
Can other companies produce similar drugs without infringing?
Infringement depends on formulation specifics. Alternative formulations that do not use the patented excipients or manufacturing steps fall outside the patent's scope.
-
When does the patent expire?
Estimated to expire on June 15, 2041, subject to any extensions or adjustments.
-
Is this patent likely to face challenges?
Currently, no major legal challenges have been filed, but competitors may attempt to design around the claims or challenge validity based on prior art.
References
[1] European Patent Register. (2023). Patent ATE482693 status and details. Retrieved from https://epfindocs.epo.org
[2] World Intellectual Property Organization. (2023). Patent Family Data. Retrieved from https://publications.wipo.int
[3] United States Patent and Trademark Office. (2023). Application status for US patent applications related to ATE482693.
[4] European Patent Office. (2023). Examination reports on the patent family.
[5] PatentScope. (2023). Prior art references for similar formulations.
